Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
TRNG | Paris | EUR | Real-time | |
TNGp | BATS Europe | EUR | Delayed | |
0OCQ | London | EUR | Real-time |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | - | - | - | - | - |
Technical Indicators | - | - | - | - | - |
Summary | Neutral | Neutral | Neutral | Neutral | Neutral |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Belt Hold Bearish | 1M | Current | |||
Completed Patterns | |||||
Downside Gap Three Methods | 1M | 1 | Jan 23 | ||
Tri-Star Bullish | 1H | 2 | Jun 28, 2023 12:00 | ||
Tri-Star Bullish | 1D | 4 | Jan 19, 2023 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
Paris | 1.140 | 0.000 | 0.000 | 56,363 | +2.52% | EUR | |||
BATS Europe | 1.850 | 1.600 | 0.000 | 0 | 0.00% | EUR | |||
London | 1.102 | 0.000 | 0.000 | 0 | 0.00% | EUR |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
IAG | 176.75 | 177.70 | 170.95 | +5.25 | +3.06% | 34.56M | 16:35:59 | ||
Rolls-Royce Holdings | 426.70 | 430.50 | 411.40 | +4.70 | +1.11% | 16.81M | 16:35:59 | ||
Lloyds Banking | 51.76 | 52.54 | 51.57 | +0.09 | +0.17% | 157.24M | 16:35:59 | ||
Barclays | 183.20 | 185.74 | 182.82 | +1.68 | +0.93% | 48.73M | 16:35:59 | ||
Vodafone Group PLC | 70.460 | 70.720 | 69.700 | +1.040 | +1.50% | 65.30M | 16:35:59 | ||
Avacta Group | 49.75 | 50.00 | 48.40 | +0.75 | +1.53% | 3.37M | 16:35:59 | ||
M&G | 220.50 | 233.55 | 219.80 | -14.30 | -6.09% | 9.42M | 16:35:59 | ||
BP | 495.70 | 498.75 | 493.30 | +2.90 | +0.59% | 35.58M | 16:35:59 | ||
EasyJet | 570.80 | 572.80 | 556.40 | +13.20 | +2.37% | 4.63M | 16:35:59 | ||
HSBC | 619.00 | 627.50 | 618.00 | +4.00 | +0.65% | 19.68M | 16:35:59 |
Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review